Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvoraleimab + bevacizumab + pemetrexed + cisplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy is a multi-modality regimen being investigated for the first-line treatment of advanced mesothelioma. It consists of two immune checkpoint inhibitors developed by Qilu Pharmaceutical: iparomlimab (an anti-PD-1 monoclonal antibody) and tuvoraleimab (an anti-CTLA-4 monoclonal antibody), which are co-formulated as the bifunctional MabPair product QL1706. These immunotherapies are combined with bevacizumab, an anti-angiogenic monoclonal antibody targeting VEGF, and a standard chemotherapy doublet of pemetrexed and cisplatin (or carboplatin). The regimen aims to leverage synergistic effects by simultaneously enhancing T-cell activation, inhibiting tumor angiogenesis, and inducing cytotoxic cell death. A Phase II trial sponsored by Fudan University is currently evaluating the efficacy and safety of this five-drug combination in patients with advanced mesothelioma.
- Other names
- QL1706 + bevacizumab + pemetrexed + cisplatiniparomlimab + tuvonralimab + bevacizumab + pemetrexed + cisplatiniparomlimab + tovorilimab + bevacizumab + pemetrexed + cisplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)DNAGART (GAR transformylase)
Beyond the preview
Go deeper on iparomlimab + tuvoraleimab + bevacizumab + pemetrexed + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvoraleimab + bevacizumab + pemetrexed + cisplatin.